A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas

PHASE1CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

August 30, 2021

Study Completion Date

June 13, 2022

Conditions
Solid TumorLymphoma
Interventions
DRUG

CS1003 monoclonal antibody

CS1003 will be administered intravenously every 3 weeks.

Trial Locations (17)

Unknown

Beijing Cancer Hospital, Beijing

Peking Union Medical College Hospital, Beijing

Peking University Third Hospital, Beijing

The First Hospital of Jilin University, Changchun

Hunan Cancer Hospital, Changsha

West China Hospital Sichuan University, Chengdu

Guangdong Provincial People's Hospital, Guangzhou

Zhejiang Cancer Hospital, Hangzhou

Harbin Medical University Cancer Hospital, Harbin

Yunnan Cancer Hospital, Kunming

The First Affiliated Hospital of Nanchang University, Nanchang

Huashan Hospital Fudan University, Shanghai

Shanghai East Hospital, Shanghai

Shanghai pulmonary hospital, Shanghai

Zhongshan Hospital, Shanghai

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Henan Cancer Hospital, Zhengzhou

Sponsors
All Listed Sponsors
lead

CStone Pharmaceuticals

INDUSTRY

NCT03809767 - A Study of CS1003 in Subjects With Advanced Solid Tumors or Lymphomas | Biotech Hunter | Biotech Hunter